View Work Group Report on Immunoglobulin

The Primary Immunodeficiency Committee has updated their recommendations on the use of immunoglobulin for primary immunodeficiency and other diseases. In the update, committee members reviewed the best practices and possible adverse effects in the application of immunoglobulin therapy in diseases where clinical indications for IV immunoglobulin have been licensed by the FDA and other diseases where the therapy shows promise. The document is meant to amend the 2006 AAAAI evidence-based guideline. 

You can access the full article here. It will also be printed as a supplement to the March issue of The Journal of Allergy and Clinical Immunology.

Thank you to the Primary Immunodeficiency Committee for their contributions.